172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2

Hasan Tahir; Helena Marzo-Ortega; Clarence W Legerton; Joachim Sieper; Alan Kivitz; Ricardo Blanco; Martin Cohen; Evie Maria Delicha; Susanne Rohrer; Hanno B Richards

Journal ArticleOPEN ACCESS

172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2

Tahir H
Marzo-Ortega H
Legerton C
et al.

Rheumatology (2018) 57(suppl_3)

DOI: 10.1093/rheumatology/key075.396

N/ACitations

6Readers

Abstract

… CG are employees of Novartis and has stocks/shares in the company. LR is an employee of … with physical function with an over 80% retention rate through to three years in patients with …

Cite

CITATION STYLE

APA

Tahir, H., Marzo-Ortega, H., Legerton, C. W., Sieper, J., Kivitz, A., Blanco, R., … Richards, H. B. (2018). 172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. Rheumatology, 57(suppl_3). https://doi.org/10.1093/rheumatology/key075.396

172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2

Abstract

Cite

Register to see more suggestions